717878-06-3

Basic information

• Product Name: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole
• Synonyms: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole
• CAS NO: 717878-06-3
• Molecular Formula: C₉H₆FN₃O₂
• Molecular Weight: 207.1612432
• Mol File: 717878-06-3.mol

Chemical Properties

• Boiling Point: 366.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.29±0.61(Predicted)
• CAS DataBase Reference: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole(717878-06-3)
• EPA Substance Registry System: 1-(4-fluorophenyl)-4-nitro-1H-iMidazole(717878-06-3)

Safety Data

• Hazardous Substances Data: 717878-06-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-fluorophenyl)-4-nitro-1H-imidazole is used as a chemical intermediate for the development of new drugs due to its antimicrobial and antiprotozoal properties. Its potential application lies in creating medications to treat a variety of microbial infections and parasitic diseases, addressing the need for novel therapeutic options in this area.
Used in Medicinal Chemistry Research:
As a nitroimidazole derivative, 1-(4-fluorophenyl)-4-nitro-1H-imidazole serves as a subject of interest in medicinal chemistry research. Scientists are likely to explore its pharmacological properties, including how it interacts with biological targets and its potential therapeutic uses, to better understand its full range of applications in drug development.
Further research is necessary to fully comprehend the compound's pharmacological properties and its potential therapeutic uses, which could lead to significant advancements in the treatment of various diseases caused by microbial and parasitic pathogens.

Upstream product

• 19182-81-1 1,4-dinitro-1H-imidazole 
• 371-40-4 4-fluoroaniline 

Relevant articles and documents

NOVEL COMPOUNDS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis

Nitroimidazoles are a well-known class of antibacterial and antiprotozoal drugs but in spite of the widespread clinical and veterinary use of these drugs, this family has been stigmatized in part due to associated genotoxicity problems. Here we report the synthesis, the anti-trypanosomal activity and a structure-activity relationship (SAR) study of a series of about fifty 1-aryl-4-nitro-1H-imidazoles, with an emphasis on selected in vivo active molecules. Compounds 4-nitro-1-{4-(trifluoromethoxy)phenyl}-1H-imidazole and 1-(3,4-dichlorophenyl)-4-nitro-1H-imidazole are curative in mouse models of both acute and chronic African trypanosomiasis when given orally at doses of 25-50 mg/kg for 4 days for the acute infection, and 50-100 mg/kg (bid) for 5 days in the chronic model. While both compounds are bacterial mutagens, activity is lost in strains lacking bacterial specific nitro-reductases. Mammalian nitro-reductases do not reduce nitroaromatic compounds with low redox potentials with same avidity as their bacterial counterparts and these compounds were shown to be devoid of genotoxicity in mammalian cells. Both compounds are promising leads for the treatment of human African trypanosomiasis (HAT or sleeping sickness), including the fatal stage 2 of the disease, for which new treatments are urgently needed.

Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds

Spiroindoline urea derivatives, designed to act as NPY Y5 receptor antagonists, were synthesized and their structure-activity relationships were investigated. Of these derivatives, compound 3a showed good Y5 binding affinity with favorable pharmacokinetic

Synthesis and characterization of some 1-halophenyl-4-nitroimidazoles

Several 1-(chloro, fluoro, dichloro or difluorophenyl)-4-nitroimidazoles and their 2-methy 1 derivatives have been prepared by the reaction of respectively substituted anilines with 1,4-dinitroimidazoles via a degenerated imidazole ring transformation. Th